Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5XCRQ)

Drug Name

R552 Drug Info

Synonyms

2-(Methylthio)thiazole; 5053-24-7; 2-Methylthiothiazole; 2-methylthio thiazole; 2-Methylthio-1,3-thiazole; Thiazole, 2-(methylthio)-; 2-methylsulfanyl-1,3-thiazole; 2-(methylsulfanyl)-1,3-thiazole; MFCD00858981; ACMC-209knn; 2-(methylthio) thiazole; 2-methylsulfanyl-thiazole; 2-(Methylmercapto)thiazole; 2-Methylthiothiazole, 97%; C4H5NS2; SCHEMBL496215; DTXSID60375024; ZINC2570798; ANW-31041; AKOS006223218; GS-6827; FT-0658231; M1712; A828155; Q-100565

Indication

Disease Entry	ICD 11	Status	REF
Nervous system paraneoplastic or autoimmune disorders	8E4A.1	Phase 1	[1]

Cross-matching ID

PubChem CID: 2760100
CAS Number: CAS 5053-24-7
TTD Drug ID: DM5XCRQ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Receptor-interacting protein 1 (RIPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK2982772	DM7HNFV	Plaque psoriasis	EA90.0	Phase 2	[3]
DNL758	DM89D6C	Cutaneous lupus erythematosus	EB5Z	Phase 2	[2]
Eclitasertib	DM2O8VW	Ulcerative colitis	DD71	Phase 2	[4]
SAR443820	DMNCP7B	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[5]
GSK3145095	DM059OH	Pancreatic cancer	2C10	Phase 1/2	[6]
DNL747	DMNSC0O	Alzheimer disease	8A20	Phase 1	[2]
DNL104	DMOSCQ9	Alzheimer disease	8A20	Phase 1	[7]
Tricyclic compound 10	DMV1RQX	N. A.	N. A.	Patented	[8]
Tricyclic compound 8	DMZI8GK	N. A.	N. A.	Patented	[8]
Tricyclic compound 9	DMF5E6U	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Receptor-interacting protein 1 (RIPK1)	TTAIQSN	RIPK1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Rigel.
2	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5	ClinicalTrials.gov (NCT05237284) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension. U.S.National Institutes of Health.
6	Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
7	DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414.
8	Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256.